Amylyx Pharmaceuticals (NASDAQ:AMLX) has priced a public offering of ~17.14M shares of its common stock at $3.50 a share. In addition, Amylyx has granted the underwriter a 30-day option to purchase up ...

Amylyx Pharmaceuticals, Inc. (AMLX), a Massachusetts-based biopharmaceutical company, Friday announced the pricing of an underwritten ...

Pharmaceuticals announced that it has commenced an underwritten public offering of shares of its common stock. Amylyx intends to ...

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced the pricing of an underwritten public offering of 17,142,857 shares of its common stock at a public offering ...

Amylyx Pharmaceuticals has named Dan Monahan as chief commercial officer, positioning an exec who led the U.S.

Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...

Dan Monahan, the exec who led Otsuka’s commercialization of Rexulti and Abilify Maintena, is taking command of the launch of ...

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...

We recently published a list of the 12 Best Biotech Penny Stocks To Invest In Now. In this article, we are going to take a ...

Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and ...

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the appointment of Dan Monahan as Chief Commercial Officer. Mr. Monahan will also join the Company’s Leadership ...

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares are being ...